General InformationRejuvenate Bio is a Massachusetts-based biotech company with 11-50 employees, founded in 2018, developing in vivo cellular reprogramming therapies to reverse aging and age-related diseases.
Funding & FinancialsThe company has raised multiple rounds including Series B funding, backed by notable deep-tech and longevity-focused investors, with total funding in the range of $10-15M.
Leadership & TeamFounded by Salk Institute researchers including Noah Z. Gordon and Juan Carlos Izpisúa Belmonte, bringing expertise in cellular reprogramming and epigenetics to the executive team.
Recent ActivityRecent focus has been on advancing their lead programs combining gene therapy with epigenetic reprogramming factors, with ongoing development of therapies targeting conditions like heart disease and neurodegeneration.